Clinical Trials Browser

Phase EARLY_PHASE1 × Carcinoma, Non-Small-Cell Lung × 90 days × Clear all

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05493566 2026-02-12

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Phase EARLY_PHASE1 Recruiting

15 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05620342 2026-02-05

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Phase EARLY_PHASE1 Recruiting

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06639191 2026-01-30

AKIR001

Phase EARLY_PHASE1 Recruiting

15 enrolled

EndocrineGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Vulvar Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06653023 2026-01-20

Wondercel-UWD3

Phase EARLY_PHASE1 Recruiting

60 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

Clinical Trials

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

AKIR001

Wondercel-UWD3